Best of iHub

[Couch]

ELTP .384 Healthy pullback ALERT from .443 - NDA FILING ON THE WAY $$$$$

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Elite intends to submit a New Drug Application to the U.S. Food and Drug Administration for abuse-deterrent ELI-200 by year-end.

"I am pleased with completing this important step in the commercialization of our first abuse-deterrent product, ELI-200," said Nasrat Hakim, President and Chief Executive Officer of Elite. "The next significant step will be the submission of the NDA for ELI-200 which I expect to occur by year-end."